Article Sidebar
Views pdf: 120
OVERALL SURVIVAL IN STAGE IIIC-IV EGFR-MUTATED NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH AFATINIB IN HANOI
Main Article Content
Abstract
Objective: This study aims to assess the overall survival (OS) outcomes of Afatinib in patients with advanced-stage epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) in Hanoi. Materials and Methods: A retrospective cohort study was conducted on 226 patients diagnosed with stage IIIC-IV EGFR-mutated NSCLC who received Afatinib treatment between June 2018 and June 2022 at six hospitals in Hanoi. Results: The median overall survival (mOS) was 34.1 months (range: 3.3–58.5 months). The 1-year and 2-year OS rates were 92.5% and 76.6%, respectively. Female patients showed a significantly longer mOS compared to male patients (35.4 vs. 33.1 months, p = 0.005). Patients harboring common EGFR mutations demonstrated a superior mOS of 38.3 months, significantly longer than those with uncommon EGFR mutations (30.9 months, p < 0.001). A statistically significant difference in OS was observed between never-smokers and smokers, with mOS of 35.4 and 28.3 months, respectively (p < 0.001). Conclusion: Afatinib is an effective targeted therapy for prolonging overall survival in patients with stage IIIC-IV EGFR-mutated NSCLC, with particularly favorable outcomes observed in female patients, never-smokers, and those with common EGFR mutations.
Article Details
Keywords
Overall survival, non-small cell lung cancer, Afatinib, EGFR mutation
References
2. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Version 3.2025 -January 14, 2025
3. Tu Anh Do, Hoa Thi Thai Nguyen, Phuong Cam Pham, et al. Efficacy and Tolerance of First-Line Afatinib in Elderly NSCLC Patients with EGFR Mutations in Vietnam: A Multicenter Real-World Study. Asian Pac J Cancer Prev.2024; 25(10): 3567–3576
4. Keunchil P, Eng H.T, Prof Ken O.B, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label. Lancet Oncol. 2016 May;17(5):577-89
5. Yi C.C, Ming J.T, Mei H.L, et al. Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations. BMC Cancer. 2021; 21(1): 495.
6. Mau E.P, Chee S.C, Chong K.L, et al. Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?. Transl Lung Cancer Res. 2024 Feb 28;13(2):307–320.
7. Jian X, Liang Z, Bixiu H, Qiong C. Impact of Sex and Smoking on the Efficacy of EGFR-TKIs in Terms of Overall Survival in Non-small-Cell Lung Cancer: A Meta-Analysis. Front Oncol. 2020 Aug 25:10:1531.
8. Joseph A.P, Carlos S.V, Luis E.R, et al. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. ESMO Open. 2018 Apr 13;3(3):e000344.
9. Juwhan C, Chang M.C, Yoon S.C, et al. Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data. Transl Lung Cancer Res. 2023 Nov 30;12(11):2275-2282
10. Zexun M, Meifeng Y, Hua H, et al. Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis. Clin Med Insights Oncol. 2023 Dec 12:17: 11795549231215968